Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension

Journal of Clinical Pharmacology

Volumn 52, Issue 12, 2012, Pages 1784-1805

  Venitz, Jürgen ^a   Zack, Julia ^b   Gillies, Hunter ^b   Allard, Martine ^b   Regnault, Jean ^b   Dufton, Christopher ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b GILEAD SCIENCES   (United States)

^c Rubicon Sciences LLC   (United States)

Author keywords

ambrisentan; bosentan; drug drug interaction; endothelin receptor antagonist; pharmacokinetics; pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; CONTRACEPTIVE AGENT; CYCLOSPORIN A; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DIGOXIN; ENDOTHELIN RECEPTOR ANTAGONIST; ETHINYLESTRADIOL PLUS NORETHISTERONE; GLIBENCLAMIDE; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2B7; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; PHOSPHODIESTERASE V INHIBITOR; RIFAMPICIN; RITONAVIR; SILDENAFIL; SIMVASTATIN; TACROLIMUS; TADALAFIL; WARFARIN;

AMINOTRANSFERASE BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; LIVER INJURY; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; HUMANS; HYPERTENSION, PULMONARY; PHENYLPROPIONATES; PYRIDAZINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 84867572006     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011423662     Document Type: Review

References (53)

1. Tuder RM, Abman SH, Braun T, et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol. 2009 ; 54 (1). S3 - S9
2. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 ; 54 (1). S55 - S66
3. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 ; 54 (1). S78 - S84
4. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 ; 126 (1). 35S - 62S
5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009 ; 54 (1). S43 - S54
6. Davenport AP, O'Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol. 1995 ; 114 (6). 1110-1116
7. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004 ; 61 (2). 227-237
8. Kirchengast M, Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med. 1999 ; 221 (4). 312-325
9. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998 ; 97 (8). 752-756
10. Foster City, CA: Gilead Sciences, Inc ; 2011
11. South San Francisco, CA: Actelion Pharmaceuticals US ; 2011 :
12. Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampin, and sildenafil. Drug Metab Dispos. 2007 ; 35 (8). 1400-1407
13. Van Giersbergen PL, Popescu G, Bodin F, Dingemanse J. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol. 2003 ; 43 (1). 15-22
14. Van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol. 2002 ; 53 (6). 589-595
15. Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1999 ; 39 (8). 847-854
16. Weber C, Banken L, Birnboeck H, Nave S, Schulz R. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol. 1999 ; 47 (6). 701-706
17. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008 ; 64 (1). 43-50
18. Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol. 2008 ; 48 (5). 640-618
19. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011 ; 30 (6). 632-643
20. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 ; 149 (8). 521-530
21. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 ; 174 (11). 1257-1263
22. Van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther. 2006 ; 44 (3). 113-118
23. Packer M, Caspi A, Charlon V, et al. Multicentre, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure: results of the REACH-1 trial [abstract]. Circulation. 1998 ; 98: 12
24. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001 ; 69 (4). 223-231
25. Van Giersbergen PL, Treiber A, Clozel M, Bodin F, Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther. 2002 ; 71 (4). 253-262
26. Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol. 2010 ; 88 (6). 682-691
27. Mano Y, Usui T, Kamimura H. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos. 2006 ; 28 (1). 13-18
28. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 ; 118 (2). 422-430
29. Dingemanse J, Schaarschmidt D, Van Giersbergen PL. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003 ; 42 (3). 293-301
30. Vavricka SR, Van MJ, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampin with organic anion uptake systems of human liver. Hepatology. 2002 ; 36 (1). 164-172
31. Van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther. 2007 ; 81 (3). 414-419
32. Dingemanse J, Van Giersbergen PL, Patat A, Nilsson PN. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther. 2010 ; 15 (2). 157-163
33. Binet I, Wallnofer A, Weber C, Jones R, Thiel G. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 2000 ; 57 (1). 224-231
34. Richards DB, Walker GA, Mandagere A, Magee MH, Henderson LS. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 2009 ; 49 (6). 719-724
35. Walker G, Mandagere A, Dufton C, Venitz J. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol. 2009 ; 67 (5). 527-534
36. Richards DB, Spence R, Mandagere A, Henderson LS, Magee MH. Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers. J Clin Pharmacol. 2011 ; 51 (1). 102-106
37. Spence R, Mandagere A, Dufton C, Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol. 2008 ; 48 (12). 1451-1459
38. Spence R, Mandagere A, Harrison B, Dufton C, Boinpally R. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci. 2009 ; 98 (12). 4962-4974
39. Spence R, Mandagere A, Walker G, Dufton C, Boinpally R. Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study. Clin Drug Investig. 2010 ; 30 (5). 313-324
40. Harrison B, Magee MH, Mandagere A, et al. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. Clin Drug Investig. 2010 ; 30 (12). 875-885
41. Gillies H, Wang X, Staehr P, Zack J. PAH therapy in HIV: lack of drug-drug interaction between ambrisentan and ritonavir. American Thoracic Society International Conference, Denver, CO, USA [abstract]. Am J Respir Crit Care Med. 2011 ; 183: A5913
42. Spence R, Mandagere A, Richards DB, et al. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 ; 88 (4). 513-520
43. Mandagere A, Coar B, Bird S, Bingham J, Boinpally R. Steady-state tacrolimus has no effect on the steady-state pharmacokinetics of ambrisentan in healthy subjects. American Thoracic Society International Conference, New Orleans, LA, USA [abstract]. Am J Respir Crit Care Med ; 2010 ; 2010. A3352.
44. Picard N, Ratanasavanh D, Premaud A, Le MY, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 ; 33 (1). 139-146
45. Mandagere A, Coar B, Bird S, Bingham J, Boinpally R. Absence of a clinically relevant pharmacokinetic interaction between ambrisentan and mycophenolate mofetil. American Thoracic Society International Conference, New Orleans, LA, USA [abstract]. Am J Respir Crit Care Med. 2010 ; 181: A3356
46. Harrison B, Despain D, Mandagere A, Walker G, Dufton C. Omeprazole has no clinically relevant effect on the pharmacokinetics of ambrisentan. American Thoracic Society International Conference, San Diego, CA, USA [abstract]. Am J Respir Crit Care Med. 2009 ; 179: A3348
47. Middlesex, UK: GlaxoSmithKline ; 2011 :
48. Galie N, Olschewski H, Oudiz R, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) study 1 and 2. Circulation. 2008 ; 117 (23). 3010-3019
49. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 ; 54 (21). 1971-1981
50. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005 ; 25: 244-249
51. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2008 ; 135 (1). 122-129
52. Jackson EA, McLaughlin V. The metabolic syndrome and pulmonary vascular disease. Chest. 2009 ; 136 (1). 3-4
53. Van Giersbergen PL, Gnerre C, Treiber A, Dingemanse J, Meyer UA. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur J Pharmacol. 2002 ; 450 (2). 115-121